These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17495874)

  • 1. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
    Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
    Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of itraconazole metabolites in CYP3A4 inhibition.
    Isoherranen N; Kunze KL; Allen KE; Nelson WL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1121-31. PubMed ID: 15242978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
    Kunze KL; Nelson WL; Kharasch ED; Thummel KE; Isoherranen N
    Drug Metab Dispos; 2006 Apr; 34(4):583-90. PubMed ID: 16415110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
    Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
    Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.
    Quinney SK; Galinsky RE; Jiyamapa-Serna VA; Chen Y; Hamman MA; Hall SD; Kimura RE
    Drug Metab Dispos; 2008 Jun; 36(6):1097-101. PubMed ID: 18339815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
    Templeton I; Peng CC; Thummel KE; Davis C; Kunze KL; Isoherranen N
    Clin Pharmacol Ther; 2010 Oct; 88(4):499-505. PubMed ID: 20739919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole.
    Mino Y; Naito T; Watanabe T; Yamada T; Yagi T; Yamada H; Kawakami J
    Clin Chim Acta; 2013 Jan; 415():128-32. PubMed ID: 23089073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A.
    Krasulova K; Dvorak Z; Anzenbacher P
    Xenobiotica; 2019 Jan; 49(1):36-42. PubMed ID: 29320899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
    Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
    Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry.
    Liang X; Van Parys M; Ding X; Zeng N; Bi L; Dorshort D; McKnight J; Milanowski D; Mao J; Chen Y; Ware JA; Dean B; Hop CE; Deng Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():111-9. PubMed ID: 27038403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T; Hisaka A; Sugiyama Y; Ito K
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
    Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.
    Peng CC; Shi W; Lutz JD; Kunze KL; Liu JO; Nelson WL; Isoherranen N
    Drug Metab Dispos; 2012 Mar; 40(3):426-35. PubMed ID: 22106171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
    Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interleukin 6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes.
    Gubbins PO; Melchert RB; McConnell SA; Franks AM; Penzak SR; Gurley BJ
    Pharmacology; 2003 Apr; 67(4):195-201. PubMed ID: 12595750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including
    Imoto Y; Mino Y; Naito T; Ono T; Kawakami J
    J Pharm Health Care Sci; 2020; 6():11. PubMed ID: 32391164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.
    Ni L; Yu X; Yu Q; Chen X; Jia L
    Drug Metab Lett; 2008 Aug; 2(3):163-8. PubMed ID: 19356088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.